Home > Healthcare > Pharmaceuticals > Finished Drug Form > Oxycodone Drugs Market

Oxycodone Drugs Market Trends

Report ID: GMI9228
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Oxycodone Drugs Market Trends

The increasing prevalence of pain serves as a significant driver for the growth of the market. Chronic pain conditions, such as arthritis, back pain, neuropathic pain, and cancer-related pain, affect millions of individuals worldwide. For instance, as per the report published by U.S. Pain Foundation in 2022, 50 million Americans live with chronic pain, or pain that lasts most days or every day for three months or more. Of this group, 20 million suffer from high-impact chronic pain, or pain that interferes with basic functioning and activities of daily living, like personal hygiene and household chores.
Similarly, as the population ages and lifestyles change, the burden of chronic pain continues to rise. In response to this, the growing need for effective pain management drugs, such as opioid analgesics like oxycodone is used to provide relief to patients experiencing moderate to severe pain. Thus, the increase in the prevalence of chronic pain owing to musculoskeletal diseases, injuries, or post-surgical procedures is expected to boost the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Oxycodone drugs industry size was USD 5.4 billion in 2023 and is projected to showcase 5.7% CAGR from 2024 to 2032, owing to the rise in incidence of chronic pain diseases like cancer, neuropathic disease, and musculoskeletal disorders.

The long-acting oxycodone segment in the market reached USD 3.4 billion in 2023 and is estimated to grow at substantial CAGR between 2024 and 2032, due to their convenience of less frequent dosing.

North America oxycodone drugs industry accumulated 42.7% revenue share in 2023 and is predicted to grow at notable rate between 2024 and 2032, owing to the increase in incidence of cancer and the rising trend of drug prescription to manage cancer-related pain.

Alvogen, Ani Pharmaceuticals, Inc., Daiichi Sankyo Company Ltd., Endo Pharmaceuticals, Mallinckrodt Pharmaceuticals, Mylan N.V., Protega Pharmaceuticals LLC, Purdue Pharma LP, Quagen Pharma, and Teva Pharmaceuticals, Inc.